FDA Pulls Plug on Two Drugs at Companies' Own Request
Published Date: 5/30/2025
Notice
Summary
The FDA is officially pulling the plug on two drug approvals from Meda AB and B. Braun Medical, Inc. because the companies told the FDA they stopped selling these drugs. This means these drugs won’t be available anymore, but no one will lose money or face surprises since the companies asked for this. If you used these drugs, it’s time to check with your doctor for alternatives!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Two Drugs Removed From Market
The FDA is withdrawing approval of two new drug applications from Meda AB and B. Braun Medical, Inc. because those companies told the FDA they stopped marketing the products and asked for withdrawal. The drugs will no longer be available, and the FDA says no one will lose money or face surprises because the companies requested this; if you used these drugs, check with your doctor about alternatives.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-09780, Agency Information Collection Proposed Extension
The Energy Information Administration (EIA) wants to keep collecting important info on natural gas liquids and oil and gas reserves for three more years, with some updates to the forms. They’re also keeping one survey paused for now. If you’re involved in the energy industry, this affects you, and the EIA is asking for your thoughts before moving forward—so don’t miss the chance to weigh in!
Next: 2025-09782, Polypropylene Corrugated Boxes From the People's Republic of China: Postponement of Preliminary Determination in the Countervailing Duty Investigation
The U.S. is investigating if Chinese polypropylene corrugated boxes get unfair government help. The first big decision on this is delayed from June 11 to a later date to give everyone more time to cooperate and sort out tricky details. This affects importers, manufacturers, and anyone watching trade rules, with possible impacts on duties and prices down the line.